mifepristone has been researched along with nalbuphine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carles, G; El Guindi, W; Largeaud, M; Montoya, Y; Perotti, F; Seve, B | 1 |
1 review(s) available for mifepristone and nalbuphine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for mifepristone and nalbuphine
| Article | Year |
|---|---|
[Medical termination of pregnancy at 9-14 weeks gestation. Prospective study of 105 cases in Saint-Laurent-du-Maroni (French Guyana)].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Legal; Administration, Intravaginal; Administration, Oral; Administration, Sublingual; Adolescent; Adult; Analgesics, Opioid; Drug Therapy, Combination; Female; Humans; Length of Stay; Mifepristone; Misoprostol; Nalbuphine; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Safety; Time Factors; Treatment Outcome | 2004 |